Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm
Key facts
- Who runs it
- University of Nebraska
- Where
- Omaha, United StatesSee the site
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 13 Apr 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- isotretinoin
- Human chorionic gonadotrophin (hCG)
- Record updated
- 20 April 2026
Who can take part
- Age
- 19 years to 50 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Male participants aged 19 to 50 years
- Confirmed diagnosis of oligospermia (sperm concentration <15 million/mL), nonobstructive azoospermia, or hypogonadotropic hypogonadism (defined by low or normal FSH with low testosterone)
- Normal genetic evaluation if diagnosed with azoospermia
- No other identified and correctable cause of infertility
- Considered appropriate candidates for medical therapy for infertility in the clinical judgment of the investigators
- Willing and able to comply with study procedures, including laboratory testing, semen analyses, and follow-up visits
- Able to provide informed consent
Who cannot take part
- Obstructive azoospermia (including vasal obstruction, ejaculatory duct obstruction, or prior vasectomy)
- Prior successful medical therapy for infertility
- Current or recent use of medications known to impair spermatogenesis, including exogenous testosterone or anabolic steroids, unless discontinued with adequate washout
- Contraindications to isotretinoin (including significant liver disease or uncontrolled hyperlipidemia)
- Contraindications to human chorionic gonadotropin (including hormone-sensitive malignancy)
- Significant medical or psychiatric conditions that, in the opinion of the investigators, would interfere with safe participation
- Current use of isotretinoin for any indication
- Inability to provide semen samples
- Inability to provide informed consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 19 and 50 years old?
Where in United States
- University of Nebraska Medical CenterOmaha, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This study compares two medical treatments to see how well they improve sperm production in men with infertility due to low sperm counts (oligospermia) or no sperm in the semen due to non-obstructive causes (nonobstructive azoospermia). Some men with these conditions have limited nonsurgical treatment options, and current therapies do not work for everyone.
Read full original descriptionShow less
Participants in this study will be adult men ages 19 to 50 who have been diagnosed with oligospermia or nonobstructive azoospermia and do not have a correctable cause for infertility. Eligible participants will be randomly assigned to receive one of two treatments for three months: oral isotretinoin taken twice daily, or human chorionic gonadotropin (hCG) injections given three times per week. hCG is a standard hormonal therapy used in certain types of male infertility, while isotretinoin is being studied for its potential role in stimulating sperm production.
At the start of the study, participants will have blood tests to measure reproductive hormone levels and a semen analysis. Blood tests will be repeated at one month and three months, and a repeat semen analysis will be performed at three months, which corresponds to a full cycle of sperm development. The main goal of the study is to determine whether motile (moving) sperm appear in the semen after treatment. Additional goals include measuring changes in sperm count and hormone levels, as well as monitoring medication side effects.
Both study medications are FDA-approved and have known side effect profiles. Participants may or may not experience improvement in sperm production. The results of this study may help guide future treatment options for men with infertility due to low or absent sperm production.
The 2 groups in the trial
- Isotretinoin Treatment ArmTreatment being tested
Participants in this arm will receive oral isotretinoin 20 mg twice daily for 3 months. Reproductive hormone testing will be performed at baseline, 1 month, and 3 months, and a semen analysis will be repeated at 3 months to assess treatment response.
Treatment: isotretinoin
- hCG Treatment ArmExisting treatment, for comparison
Participants in this arm will receive human chorionic gonadotropin (hCG) injections at a dose of 2,000 units three times weekly for 3 months. Reproductive hormone testing will be performed at baseline, 1 month, and 3 months, and a semen analysis will be repeated at 3 months to assess treatment response
Treatment: Human chorionic gonadotrophin (hCG)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Comparison of Isotretinoin and hCG Therapy in Males With Oligospermia and Azoospermia
- Criteria questions
- Built from NCT07481370, who can take part
- Record updated
- 20 April 2026